When an obscurity becomes trend: social-media descriptions of tianeptine use and associated atypical drug use

References

• Defrance R, Marey C, Kamoun A. Antidepressant and anxiolytic activities of tianeptine: an overview of clinical trials. Clin Neuropharmacol. 1988;11 Suppl 2:S74–S82.
   PubMed Web of Science ®Google Scholar
• Kasper S, McEwen BS. Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs. 2008;22:15–26. doi:10.2165/00023210-200822010-00002.
   PubMed Web of Science ®Google Scholar
• Gassaway MM, Rives M-L, Kruegel AC, Javitch JA, Sames D. The atypical antidepressant and neurorestorative agent tianeptine is a μ-opioid receptor agonist. Transl Psychiatry. 2014;4:e411. doi:10.1038/tp.2014.30.
   PubMed Web of Science ®Google Scholar
• Samuels BA, Nautiyal KM, Kruegel AC, Levinstein MR, Magalong VM, Gassaway MM, Grinnell SG, Han J, Ansonoff MA, Pintar JE, et al. The behavioral effects of the antidepressant tianeptine require the mu-opioid receptor. Neuropsychopharmacology. 2017;42:2052–63.
   PubMed Web of Science ®Google Scholar
• McEwen BS, Chattarji S, Diamond DM, Jay TM, Reagan LP, Svenningsson P, Fuchs E. The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry. 2010;15:237–49.
   PubMed Web of Science ®Google Scholar
• Tobe EH, Rybakowski JK. Possible usefulness of tianeptine in treatment-resistant depression. Int J Psychiatry Clin Pract. 2013;17:313–16. doi:10.3109/13651501.2013.798418.
   PubMed Web of Science ®Google Scholar
• Woo YS, Bahk WM, Jeong JH, Lee SH, Sung HM, Pae CU, Koo B-H, Kim W. Tianeptine combination for partial or non-response to selective serotonin re-uptake inhibitor monotherapy. Psychiatry Clin Neurosci. 2013;67:219–27.
   PubMed Web of Science ®Google Scholar
• Gupta S, Wallace R, Sloshower J. Online sales of unscheduled pharmaceutical agents: a case report of tianeptine use in the United States, Journal of Addiction Medicine 2017: 11: 411–12.
   Google Scholar
• Giurgea C, Salama M. Nootropic drugs. Prog Neuropsychopharmacol. 1977;1:235–47. doi:10.1016/0364-7722(77)90046-7.
   Google Scholar
• Vadachkoria D, Gabunia L, Gambashidze K, Pkhaladze N, Kuridze N. Addictive potential of tianeptine—the threatening reality. Georgian Med News. 2009;174:92–94.
   PubMedGoogle Scholar
• Springer J, Cubała WJ. Tianeptine abuse and dependence in psychiatric patients: a review of 18 case reports in the literature. J Psychoactive Drugs. 2018;50:275–80. doi:10.1080/02791072.2018.1438687.
   PubMed Web of Science ®Google Scholar
• Bakota EL, Samms WC, Gray TR, Oleske DA, Hines MO. Case reports of fatalities involving tianeptine in the United States. J Anal Toxicol. 2018;42:503–09. doi:10.1093/jat/bky023.
   PubMed Web of Science ®Google Scholar
• El Zahran T, Schier J, Glidden E, Kieszak S, Law R, Bottei E, Aaron C, King A, Chang A. Characteristics of tianeptine exposures reported to the National Poison Data System—United States, 2000–2017. Morbidity Mortality Weekly Rep. 2018;67:815–18.
   PubMed Web of Science ®Google Scholar
• Rushton W, Whitworth B, Brown J, Kurz M, Rivera J. Characteristics of tianeptine effects reported to a poison control center: a growing threat to public health. Clin Toxicol. 2020;59:1–6.
   Web of Science ®Google Scholar
• Ahuja T, Mgbako O, Katzman C, Grossman A. Phenibut (beta-phenyl-gamma-aminobutyric acid) dependence and management of withdrawal: emerging nootropics of abuse. Case Rep Psychiatry. 2018;2018:9864285.
   PubMedGoogle Scholar
• Baumann MH, Volkow ND. Abuse of new psychoactive substances: threats and solutions. Neuropsychopharmacology. 2016;41:663–65. doi:10.1038/npp.2015.260.
   PubMed Web of Science ®Google Scholar
• Jouney EA. Phenibut (beta-phenyl-gamma-aminobutyric acid): an easily obtainable “dietary supplement” with propensities for physical dependence and addiction. Curr Psychiatry Rep. 2019;21:23. doi:10.1007/s11920-019-1009-0.
   PubMed Web of Science ®Google Scholar
• Napoletano F, Schifano F, Corkery JM, Guirguis A, Arillotta D, Zangani C, Vento A. The psychonauts’ world of cognitive enhancers. Front Psychiatry. 2020;11:546796.
   PubMed Web of Science ®Google Scholar
• Schifano F, Orsolini L, Duccio Papanti G, Corkery JM. Novel psychoactive substances of interest for psychiatry. World Psychiatry. 2015;14:15–26. doi:10.1002/wps.20174.
   PubMed Web of Science ®Google Scholar
• Corazza O, Bersani FS, Brunoro R, Valeriani G, Martinotti G, Schifano F. The diffusion of performance and image-enhancing drugs (PIEDs) on the internet: the abuse of the cognitive enhancer piracetam. Subst Use Misuse. 2014;49:1849–56. doi:10.3109/10826084.2014.912232.
   PubMed Web of Science ®Google Scholar
• Deluca P, Davey Z, Corazza O, Di Furia L, Farre M, Flesland LH, Mannonen M, Majava A, Peltoniemi T, Pasinetti M, et al. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39:221–26.
   PubMed Web of Science ®Google Scholar
• O’Brien K, Chatwin C, Jenkins C, Measham F. New psychoactive substances and British drug policy: a view from the cyber-psychonauts. Drugs: Educ Prev Policy. 2015;22:217–33.
   Web of Science ®Google Scholar
• Chilcoat HD, Amick HR, Sherwood MR, Dunn KE. Buprenorphine in the United States: motives for abuse, misuse, and diversion. J Subst Abuse Treat. 2019;104:148–57. doi:10.1016/j.jsat.2019.07.005.
   PubMed Web of Science ®Google Scholar
• Cicero TJ, Ellis MS, Chilcoat HD. Understanding the use of diverted buprenorphine. Drug Alcohol Depend. 2018;193:117–23. doi:10.1016/j.drugalcdep.2018.09.007.
   PubMed Web of Science ®Google Scholar
• Garcia-Romeu A, Cox DJ, Smith KE, Dunn KE, Griffiths RR. Kratom (Mitragyna speciosa): user demographics, use patterns, and implications for the opioid epidemic. Drug Alcohol Depend. 2020;208:107849. doi:10.1016/j.drugalcdep.2020.107849.
   PubMed Web of Science ®Google Scholar
• Kavanaugh PR, McLean K. Motivations for diverted buprenorphine use in a multisite qualitative study. J Drug Issues. 2020;50:550–65. doi:10.1177/0022042620941796.
   Web of Science ®Google Scholar
• Smith KE, Lawson T. Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program. Drug Alcohol Depend. 2017;180:340–48. doi:10.1016/j.drugalcdep.2017.08.034.
   PubMed Web of Science ®Google Scholar
• Pauly NJ, Slavova S, Delcher C, Freeman PR, Talbert J. Features of prescription drug monitoring programs associated with reduced rates of prescription opioid-related poisonings. Drug Alcohol Depend. 2018;184:26–32. doi:10.1016/j.drugalcdep.2017.12.002.
   PubMed Web of Science ®Google Scholar
• Spiller H, Lorenz DJ, Bailey EJ, Dart RC. Epidemiological trends in abuse and misuse of prescription opioids. J Addict Dis. 2009;28:130–36. doi:10.1080/10550880902772431.
   PubMed Web of Science ®Google Scholar
• Unick GJ, Rosenblum D, Mars S, Ciccarone D. Intertwined epidemics: national demographic trends in hospitalizations for heroin- and opioid-related overdoses, 1993-2009. PLoS One. 2013;8:e54496. doi:10.1371/journal.pone.0054496.
   PubMed Web of Science ®Google Scholar
• Dambrova M, Zvejniece L, Liepinsh E, Cirule H, Zharkova O, Veinberg G, Kalvinsh I. Comparative pharmacological activity of optical isomers of phenibut. Eur J Pharmacol. 2008;583:128–34.
   PubMed Web of Science ®Google Scholar
• Downes MA, Berling IL, Mostafa A, Grice J, Roberts MS, Isbister GK. Acute behavioural disturbance associated with phenibut purchased via an internet supplier. Clin Toxicol (Phila). 2015;53:636–38. doi:10.3109/15563650.2015.1059945.
   PubMed Web of Science ®Google Scholar
• Kaupmann K, Huggel K, Heid J, Flor PJ, Bischoff S, Mickel SJ, McMaster G, Angst C, Bittiger H, Froestl W, et al. Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature. 1997;386:239–46.
   PubMed Web of Science ®Google Scholar
• Lapin I. Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug. CNS Drug Rev. 2001;7:471–81. doi:10.1111/j.1527-3458.2001.tb00211.x.
   PubMedGoogle Scholar
• Wong A, Little M, Caldicott D, Easton C, Andres D, Greene SL. Analytically confirmed recreational use of Phenibut (beta-phenyl-gamma-aminobutyric acid) bought over the internet. Clin Toxicol (Phila). 2015;53:783–84. doi:10.3109/15563650.2015.1059944.
   PubMed Web of Science ®Google Scholar
• Cohen PA, Zakharevich I, Gerona R. Presence of piracetam in cognitive enhancement dietary supplements. JAMA Intern Med. 2020;180:458–59. doi:10.1001/jamainternmed.2019.5507.
   PubMed Web of Science ®Google Scholar
• Loscher W, Richter A. Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia. Eur J Pharmacol. 2000;391:251–54. doi:10.1016/S0014-2999(00)00105-9.
   PubMed Web of Science ®Google Scholar
• Prado CE, Watt S, Crowe SF. A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples. Neuropsychol Rev. 2018;28:32–72. doi:10.1007/s11065-018-9369-5.
   PubMed Web of Science ®Google Scholar
• Robinson SA, Erickson RL, Browne CA, Lucki I. A role for the mu opioid receptor in the antidepressant effects of buprenorphine. Behav Brain Res. 2017;319:96–103. doi:10.1016/j.bbr.2016.10.050.
   PubMed Web of Science ®Google Scholar
• Yovell Y, Bar G, Mashiah M, Baruch Y, Briskman I, Asherov J, Lotan A, Rigbi A, Panksepp J. Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial. Am J Psychiatry. 2016;173:491–98.
   PubMed Web of Science ®Google Scholar
• Lutz PE, Kieffer BL. Opioid receptors: distinct roles in mood disorders. Trends Neurosci. 2013;36:195–206. doi:10.1016/j.tins.2012.11.002.
   PubMed Web of Science ®Google Scholar
• Orsolini L, Papanti GD, Francesconi G, Schifano F. Mind navigators of chemicals’ experimenters? A web-based description of e-psychonauts. Cyberpsychol Behav Soc Netw. 2015;18:296–300. doi:10.1089/cyber.2014.0486.
   PubMed Web of Science ®Google Scholar
• Valeriani G, Corazza O, Bersani FS, Melcore C, Metastasio A, Bersani G, Schifano F. Olanzapine as the ideal “trip terminator”? Analysis of online reports relating to antipsychotics’ use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms. Hum Psychopharmacol. 2015;30:249–54.
   PubMed Web of Science ®Google Scholar
• Hardman MI, Sprung J, Weingarten TN. Acute phenibut withdrawal: a comprehensive literature review and illustrative case report. Bosn J Basic Med Sci. 2019;19:125–29. doi:10.17305/bjbms.2018.4008.
   PubMed Web of Science ®Google Scholar
• Magsalin RM, Khan AY. Withdrawal symptoms after Internet purchase of phenibut (beta-phenyl-gamma-aminobutyric acid HCl). J Clin Psychopharmacol. 2010;30:648–49. doi:10.1097/JCP.0b013e3181f057c8.
   PubMed Web of Science ®Google Scholar
• O’Connell CW, Schneir AB, Hwang JQ, Cantrell FL. Phenibut, the appearance of another potentially dangerous product in the United States. Am J Med. 2014;127:e3–4. doi:10.1016/j.amjmed.2014.03.029.
   PubMed Web of Science ®Google Scholar
• Owen DR, Wood DM, Archer JR, Dargan PI. Phenibut (4-amino-3-phenyl-butyric acid): availability, prevalence of use, desired effects and acute toxicity. Drug Alcohol Rev. 2016;35:591–96. doi:10.1111/dar.12356.
   PubMed Web of Science ®Google Scholar
• Samokhvalov AV, Paton-Gay CL, Balchand K, Rehm J. Phenibut dependence, BMJ Case Rep 2013: 2013.
   Google Scholar
• Henningfield JE, Fant RV, Wang DW. The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research. Psychopharmacology. 2018;235:573–89. doi:10.1007/s00213-017-4813-4.
   PubMed Web of Science ®Google Scholar
• Kruegel AC, Grundmann O. The medicinal chemistry and neuropharmacology of kratom: a preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology. 2018;134:108–20. doi:10.1016/j.neuropharm.2017.08.026.
   PubMed Web of Science ®Google Scholar
• Mun M, Wong A. Kratom and phenibut: a concise review for psychiatric trainees. Am J Psychiatry Residents’ J. 2020;16:6–8. doi:10.1176/appi.ajp-rj.2020.160203.
   Google Scholar
• Bath R, Bucholz T, Buros AF, Singh D, Smith KE, Veltri CA, Grundmann O. Self-reported health diagnoses and demographic correlates with kratom use: results from an online survey. J Addict Med. 2020;14:244–52.
   PubMed Web of Science ®Google Scholar
• Coe MA, Pillitteri JL, Sembower MA, Gerlach KK, Henningfield JE. Kratom as a substitute for opioids: results from an online survey. Drug Alcohol Depend. 2019;202:24–32. doi:10.1016/j.drugalcdep.2019.05.005.
   PubMed Web of Science ®Google Scholar
• Högberg L, Szabó I, Ruusa J. Psychotic symptoms during phenibut (beta-phenyl-gamma-aminobutyric acid) withdrawal. J Subst Use. 2013;18:335–38. doi:10.3109/14659891.2012.668261.
   Web of Science ®Google Scholar
• McCabe DJ, Bangh SA, Arens AM, Cole JB. Phenibut exposures and clinical effects reported to a regional poison center. Am J Emerg Med. 2019;37:2066–71. doi:10.1016/j.ajem.2019.02.044.
   PubMed Web of Science ®Google Scholar
• Rod W, Kudryk A, Brunetti L, Sun N, Nguyen M. Phenibut withdrawal management in the setting of concomitant kratom and alcohol dependence. Crit Care Med. 2018;46:451. doi:10.1097/01.ccm.0000528942.37373.7a.
   Web of Science ®Google Scholar
• Hockenhull J, Wood DM, Dargan PI. The availability of modafinil and methylphenidate purchased from the internet in the United Kingdom without a prescription. Subst Use Misuse. 2020;55:56–65. doi:10.1080/10826084.2019.1654516.
   PubMed Web of Science ®Google Scholar
• Teodorini RD, Rycroft N, Smith-Spark JH. The off-prescription use of modafinil: an online survey of perceived risks and benefits. PLoS One. 2020;15:e0227818.
   PubMed Web of Science ®Google Scholar
• Mazanov J, Dunn M, Connor J, Fielding ML. Substance use to enhance academic performance among Australian university students. Perform Enhancement Health. 2013;2:110–18. doi:10.1016/j.peh.2013.08.017.
   Google Scholar